Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05714410
Other study ID # 22.08.CLI
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 25, 2023
Est. completion date January 19, 2024

Study information

Verified date January 2024
Source Société des Produits Nestlé (SPN)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluation of Changes in Bowel Movement Frequency Following the Consumption of Partially Hydrolyzed Guar Gum (PHGG) in Adults With Constipation as Compared to Placebo (Typhoon 2)


Recruitment information / eligibility

Status Completed
Enrollment 160
Est. completion date January 19, 2024
Est. primary completion date January 19, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Men or women aged 18-75. 2. Adapted Rome IV Criteria of functional constipation* or IBSconstipation** for a minimum of 3 months *1-2 SBM/week and at least 1 of the following at least 30% of the time: 1. Bristol stool scale 1-2 2. Straining 3. Sense of incomplete evacuation 4. Sense of stool blockage 5. Need of digital maneuvers - Subjects with IBS-C: the above constipation criteria + abdominal pain are allowed. 3. Ability to understand the participant information sheet and instructions, and able to provide informed consent. 4. Access to a suitable smartphone device (Android or iOS) with ability to download and complete the study e-Diary daily for the duration of the trial. Exclusion Criteria: 1. Pregnant women or breastfeeding. 2. Organic chronic gastrointestinal disease or complication (such as, but not limited to, Inflammatory Bowel Disease, Microscopic colitis, Eosinophilic gastroenteritis, Radiation-related enterocolitis, Coeliac disease). 3. Subjects with a diagnosed food allergy or hypersensitive to any of the components of the study product. 4. Subjects with chronic diarrhea. 5. Active peptic ulcer. 6. Major gastrointestinal or colonic surgery (such as, gastric bypass or any other obesity or metabolic interventions including endoscopic procedures or devices, any gastro-intestinal or colonic resection); cholecystectomy and appendectomy are allowed. 7. Neurologic or other clinically significant comorbid diseases that may affect gastrointestinal function, such as multiple sclerosis, spinal cord injury or Hirschsprung disease. 8. Illness that may preclude the participant's ability to complete the study or that may confound the study outcomes (e.g. bowel cancer, prostate cancer, terminal illness, severe cardiovascular disease, chronic renal failure or eating disorders) or any other serious illness resulting in >2 weeks inability to work in the 3 months before the study start. 9. Participants with clinically significant (as per physician judgement) co-morbid illnesses such as cardiovascular, endocrine (e.g. hypothyroidism, diabetes), renal, or other chronicdisease (e.g. reduced mobility or increased fragility). 10. Active alcohol, drug, or medication abuse (as per clinician judgement). 11. Self-reported symptoms suggestive of pelvic organ prolapse as per clinician judgement, such as feeling of pressure or fullness in the pelvic area, intra vaginal discomfort, painful intercourse, and urinary problems. 12. Moderate or severe active local anorectal problems such as recurrent anal fissures, frequent bleeding, large prolapsing hemorrhoids. 13. Any clinically relevant abnormalities detected during the physical examination or any alarm features in the medical history such as sudden unintentional weight loss (>10% in 3 months), frequent rectal bleeding not caused by anal fissures or hemorrhoids, recent change in bowel habit (<3 months), severe abdominal pain and stool positive for occult blood. 14. Regular (i.e. daily or weekly) use of PHGG within 6 months of screening. 15. Participation in another study with any investigational product within 6 months of randomization for drug study and within 2 months of randomization for a nutritional study. 16. Investigator believes that the participant is physically or mentally unfit to participate in the trial. 17. Participants currently of childbearing potential, but not using an effective method of contraception, as determined by the investigator. 18. Any participant who is an employee of the study site or an Atlantia Clinical Trials employee or their close family member or a member of their household.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
PHGG
PHGG

Locations

Country Name City State
Ireland Atlantia Food Clinical Trials Cork

Sponsors (1)

Lead Sponsor Collaborator
Société des Produits Nestlé (SPN)

Country where clinical trial is conducted

Ireland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Spontaneous Bowel Movements Change in mean weekly frequency of Spontaneous Bowel Movements (SBM) as measured by the daily bowel diary from baseline to end of treatment period. Frequency will be defined as the mean weekly number of SBM during the 2-week run-in period prior to V0, for baseline, and during the final 2 weeks of the intervention period, for end of treatment. 6 weeks
Secondary Change in frequency of Complete Spontaneous Bowel Movements Change in mean weekly frequency of Complete Spontaneous Bowel Movements (CSBM) as measured by the daily bowel diary, from baseline to the end of treatment period. 6 weeks
Secondary Change in stool consistency Change in stool consistency as measured by the Bristol stool scale, from baseline to end of intervention. The minimum and maximum values are 1 to 7. The extremes scores mean worse outcome. The middle or the scale mean the better outcome. 6 weeks
Secondary Change in constipation related symptoms Change in constipation related symptoms from baseline to end of intervention as measured by the Patient Assessment of Constipation Symptoms (PAC-SYM) questionnaire. The minimum and maximum values are 1 to 48. The higher score means worse outcome. 6 weeks
See also
  Status Clinical Trial Phase
Completed NCT05032534 - Examination of a New Irrigation System for Transanal Irrigation in Children With Fecal Incontinence N/A
Completed NCT04587635 - Evaluation of Changes in Bowel Movement Frequency Following the Consumption of PHGG in Adults With Constipation N/A
Completed NCT03821532 - Adherence/Outcomes After Use of Constipation Action Plan N/A
Recruiting NCT06122558 - Efficacy of Probiotic Against Functional Constipation Phase 2
Recruiting NCT04086134 - Physiological, Microbiological and Metabolomic Effects of Fruit Products N/A
Recruiting NCT01587846 - Lactobacillus Reuteri in Treatment of Functional Abdominal Pain and Chronic Constipation in Children Phase 3
Recruiting NCT05496543 - Acupuncture for Functional Constipation in Older Adults N/A
Completed NCT05447481 - Evaluation of the Effect of Chicory Inulin-type Fructans in Constipated Adults N/A
Completed NCT05035784 - RCE With FMT in the Treatment of Childhood Constipation N/A
Recruiting NCT06221722 - Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation
Suspended NCT04306939 - Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
Recruiting NCT05823259 - The Impact of Respiratory Muscle Training and Patient Education on Chronic Constipation Outcomes N/A
Not yet recruiting NCT06438068 - Influence of Modern Colon Hydrotherapy on Intestinal Transit N/A
Withdrawn NCT05321953 - The Impact of Aerobic Interval and Inspiratory Muscle Training On Patient Reported Outcome Scores In Individuals With Chronic Constipation N/A
Active, not recruiting NCT05363553 - Transition to Infant Formula Feeding on Gastrointestinal Regurgitation (TIGER) Study N/A
Recruiting NCT06031025 - Prevalence and Natural History of Functional Gastrointestinal Disorders Among At-risk Infants.
Recruiting NCT05432453 - The Relationship Between Functional Constipation and Sacroiliac Joint Dysfunction
Not yet recruiting NCT05191810 - Efficacy of Educational Intervention as Supporting Element in the Treatment of Functional Constipation in Children N/A
Not yet recruiting NCT06100055 - The ReVo Study: Low-volume vs High-volume Rectal Irrigation N/A
Recruiting NCT04148248 - A Pilot Study to Explore the Role of Gut Flora in Chronic Constipation